Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 2.0 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HOWL. Financial Perspectives Inc grew its position in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after acquiring an additional 3,000 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Werewolf Therapeutics by 16.8% in the first quarter. Rhumbline Advisers now owns 22,550 shares of the company’s stock valued at $99,000 after buying an additional 3,245 shares during the period. Bank of New York Mellon Corp boosted its position in Werewolf Therapeutics by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 68,338 shares of the company’s stock worth $301,000 after buying an additional 3,555 shares during the period. Dimensional Fund Advisors LP increased its position in Werewolf Therapeutics by 8.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 62,923 shares of the company’s stock valued at $243,000 after acquiring an additional 4,795 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Werewolf Therapeutics by 31.0% during the second quarter. Northern Trust Corp now owns 26,067 shares of the company’s stock valued at $80,000 after acquiring an additional 6,161 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Stock Up 4.7 %

HOWL stock opened at $5.75 on Tuesday. Werewolf Therapeutics has a twelve month low of $1.57 and a twelve month high of $8.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. The business has a 50 day moving average price of $6.32 and a two-hundred day moving average price of $4.28.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.10. Werewolf Therapeutics had a negative return on equity of 32.25% and a negative net margin of 187.37%. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. On average, sell-side analysts predict that Werewolf Therapeutics will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities initiated coverage on Werewolf Therapeutics in a report on Wednesday, April 3rd. They set a “mkt outperform” rating and a $12.00 target price for the company.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.